DrugPatentWatch Database Preview
Palbociclib - Generic Drug Details
What are the generic sources for palbociclib and what is the scope of freedom to operate?
Palbociclib
is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in two NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Palbociclib has seventy-two patent family members in forty-nine countries.
There are thirteen drug master file entries for palbociclib. Three suppliers are listed for this compound.
Summary for palbociclib
| International Patents: | 72 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 13 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 89 |
| Clinical Trials: | 191 |
| Patent Applications: | 259 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for palbociclib |
| DailyMed Link: | palbociclib at DailyMed |
Recent Clinical Trials for palbociclib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Breast Cancer Now | Phase 1 |
| Ulrik Lassen | Phase 2 |
| GlaxoSmithKline | Phase 2 |
Pharmacology for palbociclib
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors Cytochrome P450 3A Inhibitors |
Paragraph IV (Patent) Challenges for PALBOCICLIB
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| IBRANCE | CAPSULE;ORAL | palbociclib | 207103 | 2019-02-04 |
US Patents and Regulatory Information for palbociclib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | IBRANCE | palbociclib | TABLET;ORAL | 212436-002 | Nov 1, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | IBRANCE | palbociclib | CAPSULE;ORAL | 207103-002 | Feb 3, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | IBRANCE | palbociclib | TABLET;ORAL | 212436-001 | Nov 1, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for palbociclib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 038814 | Start Trial |
| Serbia | 51044 | Start Trial |
| Poland | 218692 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for palbociclib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1470124 | 122017000014 | Germany | Start Trial | PRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109 |
| 1470124 | CR 2017 00010 | Denmark | Start Trial | PRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111 |
| 1470124 | 2017/009 | Ireland | Start Trial | PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESTER, AMIDE OR PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/16/1147/001 EU/1/16/1147/006 20161109 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
